PL3606942T3 - Samoorganizujące się nanostruktury białkowe zawierające białka f paramyksowirusa i/lub pneumowirusa oraz ich zastosowanie - Google Patents

Samoorganizujące się nanostruktury białkowe zawierające białka f paramyksowirusa i/lub pneumowirusa oraz ich zastosowanie

Info

Publication number
PL3606942T3
PL3606942T3 PL18723094.1T PL18723094T PL3606942T3 PL 3606942 T3 PL3606942 T3 PL 3606942T3 PL 18723094 T PL18723094 T PL 18723094T PL 3606942 T3 PL3606942 T3 PL 3606942T3
Authority
PL
Poland
Prior art keywords
pneumovirus
paramyxovirus
proteins
self
assembling protein
Prior art date
Application number
PL18723094.1T
Other languages
English (en)
Polish (pl)
Inventor
Neil P. King
David Baker
Brooke NICKERSON
Lance Joseph STEWART
Laurent Perez
Antonio Lanzavecchia
Jessica MARCANDALLI
Jorge Fallas
Yang HSIA
Original Assignee
University Of Washington
Institute For Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington, Institute For Research In Biomedicine filed Critical University Of Washington
Publication of PL3606942T3 publication Critical patent/PL3606942T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18723094.1T 2017-04-04 2018-04-03 Samoorganizujące się nanostruktury białkowe zawierające białka f paramyksowirusa i/lub pneumowirusa oraz ich zastosowanie PL3606942T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (1)

Publication Number Publication Date
PL3606942T3 true PL3606942T3 (pl) 2025-11-12

Family

ID=62116943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18723094.1T PL3606942T3 (pl) 2017-04-04 2018-04-03 Samoorganizujące się nanostruktury białkowe zawierające białka f paramyksowirusa i/lub pneumowirusa oraz ich zastosowanie

Country Status (23)

Country Link
US (4) US11192926B2 (enExample)
EP (2) EP4559869A3 (enExample)
JP (3) JP7168938B2 (enExample)
KR (2) KR20240161683A (enExample)
CN (3) CN110603262A (enExample)
AU (3) AU2018249533C1 (enExample)
BR (1) BR112019020661A2 (enExample)
CA (1) CA3058794A1 (enExample)
DK (1) DK3606942T3 (enExample)
ES (1) ES3040563T3 (enExample)
FI (1) FI3606942T3 (enExample)
HR (1) HRP20251060T1 (enExample)
IL (2) IL322023A (enExample)
LT (1) LT3606942T (enExample)
MX (2) MX2019011869A (enExample)
PH (1) PH12019502276A1 (enExample)
PL (1) PL3606942T3 (enExample)
PT (1) PT3606942T (enExample)
RS (1) RS67190B1 (enExample)
SG (1) SG11201908999QA (enExample)
SI (1) SI3606942T1 (enExample)
SM (1) SMT202500317T1 (enExample)
WO (1) WO2018187325A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
US20220306697A1 (en) * 2019-09-04 2022-09-29 University Of Washington Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
EP4096683A4 (en) * 2020-01-30 2024-04-10 ModernaTX, Inc. IMMUNIZATION COMPOSITIONS FOR RESPIRATORY VIRUSES
US20240277831A1 (en) * 2020-02-14 2024-08-22 University Of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
WO2021163481A1 (en) * 2020-02-14 2021-08-19 University Of Washington Polypeptides and their use
KR20230038465A (ko) * 2020-06-09 2023-03-20 아이코사백스, 인크. 2성분 바이러스 유사 입자를 조립하는 방법
CN116194460A (zh) * 2020-06-09 2023-05-30 Icosavax股份有限公司 制备病毒样颗粒的方法
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
WO2022103967A1 (en) 2020-11-13 2022-05-19 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
EP4384535A4 (en) * 2021-08-10 2025-06-25 Icosavax, Inc. Virus-like particle vaccine for respiratory syncytial virus
WO2023225562A1 (en) 2022-05-17 2023-11-23 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof
JP2025539418A (ja) * 2022-11-29 2025-12-05 ザ スクリプス リサーチ インスティテュート 新規ナノ粒子足場を含有するワクチン
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
TW202519273A (zh) * 2023-07-18 2025-05-16 瑞典商阿斯特捷利康公司 Rsv疫苗
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
WO2025093041A1 (zh) * 2023-11-03 2025-05-08 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
DE69924712T2 (de) 1998-03-04 2006-03-09 Exxonmobil Chemical Patents Inc., Baytown Nicht koordinierende anionen für die polymerisation von olefinen
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
JP2006500928A (ja) 2002-07-31 2006-01-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 大腸菌におけるグリコシル化マクロライドの産生
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
WO2009079796A1 (en) 2007-12-24 2009-07-02 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
PL3067064T3 (pl) 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
EP2590675B1 (en) 2010-07-07 2018-08-29 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
CA2849471A1 (en) 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington MANIPULATED OUTER DOMAIN OF HV-GP120 AND MUTANTS THEREOF
EP3511337A1 (en) 2012-04-10 2019-07-17 The Trustees of The University of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
BR112015011389A2 (pt) 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
SMT202400297T1 (it) 2013-03-13 2024-09-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Proteine f del rsv pre-fusione e loro uso
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
EP2975052B1 (en) 2013-03-15 2020-09-23 Xiamen University Epitope of rsv fusion protein and antibody identifying same
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
CA2925201A1 (en) 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
WO2015104352A1 (en) 2014-01-09 2015-07-16 Alpha-O Peptides Ag Flagellin-containing protein nanoparticles as a vaccine platform
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
MY182440A (en) 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
US10744193B2 (en) 2015-03-30 2020-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic RSV polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017027480A1 (en) 2015-08-13 2017-02-16 Echogen Power Systems, L.L.C. Heat engine system including an integrated cooling circuit
EP3344290A4 (en) 2015-08-31 2019-02-27 Technovax, Inc. VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
MA52645B1 (fr) 2015-10-22 2022-06-30 Modernatx Inc Vaccins contre le virus respiratoire
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
CN109069611B (zh) 2016-03-29 2022-11-04 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines

Also Published As

Publication number Publication date
HRP20251060T1 (hr) 2025-11-07
KR102774312B1 (ko) 2025-03-05
MX2023004704A (es) 2023-05-09
SI3606942T1 (sl) 2025-11-28
CA3058794A1 (en) 2018-10-11
ES3040563T3 (en) 2025-11-03
US20240150411A1 (en) 2024-05-09
AU2018249533A1 (en) 2019-10-17
CN115947873A (zh) 2023-04-11
RU2019130167A (ru) 2021-05-05
AU2018249533B2 (en) 2022-01-27
SMT202500317T1 (it) 2025-11-10
WO2018187325A1 (en) 2018-10-11
EP4559869A2 (en) 2025-05-28
US20220169681A1 (en) 2022-06-02
AU2022202787C1 (en) 2025-01-30
KR20240161683A (ko) 2024-11-12
MX2019011869A (es) 2020-01-09
EP3606942B1 (en) 2025-06-11
IL322023A (en) 2025-09-01
US20250263445A1 (en) 2025-08-21
US20200392187A1 (en) 2020-12-17
LT3606942T (lt) 2025-10-10
DK3606942T3 (da) 2025-09-08
CN115779077A (zh) 2023-03-14
JP2023002680A (ja) 2023-01-10
SG11201908999QA (en) 2019-10-30
EP4559869A3 (en) 2025-08-20
CN110603262A (zh) 2019-12-20
AU2024220089A1 (en) 2024-10-17
PT3606942T (pt) 2025-09-01
AU2022202787B2 (en) 2024-07-04
AU2022202787A1 (en) 2022-05-19
US11732011B2 (en) 2023-08-22
JP2024160321A (ja) 2024-11-13
RU2019130167A3 (enExample) 2021-12-22
EP3606942A1 (en) 2020-02-12
JP7168938B2 (ja) 2022-11-10
AU2018249533C1 (en) 2023-10-12
US11192926B2 (en) 2021-12-07
PH12019502276A1 (en) 2020-09-28
JP2020515280A (ja) 2020-05-28
FI3606942T3 (fi) 2025-08-29
US12275757B2 (en) 2025-04-15
JP7541701B2 (ja) 2024-08-29
IL269643A (en) 2019-11-28
BR112019020661A2 (pt) 2020-05-05
KR20190140916A (ko) 2019-12-20
RS67190B1 (sr) 2025-10-31

Similar Documents

Publication Publication Date Title
PL3606942T3 (pl) Samoorganizujące się nanostruktury białkowe zawierające białka f paramyksowirusa i/lub pneumowirusa oraz ich zastosowanie
IL273918A (en) Trispecific proteins and methods of use
ZA201808284B (en) Gdf15 fusion proteins and uses thereof
SI3596116T1 (sl) Imunomodulatorni proteini različice pd-l1 in njihove uporabe
PL3310805T3 (pl) Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie
ZA201806436B (en) Insecticidal proteins and methods for their use
SG10201912690PA (en) Protein cage-stabilized pickering emulsions and the use thereof
SI3565828T1 (sl) SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
ZA201900209B (en) Novel natural protein and application thereof
EP3201341C0 (en) HYPERSENSITIVE RESPONSE ELICITOR PEPTIDES AND THEIR USE
EP3288952A4 (en) Organotrifluoroborate mimics of amino acids and uses thereof
EP3498726A4 (en) DNA BINDING PROTEIN USING A PPR PATTERN AND USE OF SAID DNA BINDING PROTEIN
EP3441001C0 (en) POSITION SENSORS FOR IN VIVO DEVICES AND ASSOCIATED CONTROL METHODS
PL3639845T3 (pl) Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
ZA201907063B (en) Insecticidal proteins and methods for their use
EP3365353C0 (en) INTEGRIN-BINDING PEPTIDES AND THEIR USES
IL272050B1 (en) Synthetic proteins and their therapeutic uses
EP3480212C0 (en) IL13RALPHA2 PEPTIDE AND ITS USES
ZA201805797B (en) Novel alpha-1-microglobulin derived proteins and their use
EP3585798A4 (en) IN VIVO PROTEIN N ACYLATION
EP3345003A4 (en) IDENTIFICATION OF PROTEINS IN THE ABSENCE OF PEPTIDE IDENTIFICATION
HUP1700012A2 (en) Novel proteins and use thereof
HK40030279A (en) Synthetic proteins and therapeutic uses thereof
IL254205A0 (en) Amino acid acylation reagents and methods of using the same
GB201617925D0 (en) Proteins and uses